Cargando…
Depleting TMED3 alleviates the development of endometrial carcinoma
BACKGROUND: As one of gynecologic tumors, endometrial carcinoma (EC) has been characterized by high incidence rate, but its molecular pathogenesis has remained unclear. TMED3 is a membrane protein and has been indicated to implicate several tumor-related diseases. In the current study, we aimed to e...
Autores principales: | Zhang, Jin, Qi, Yue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295347/ https://www.ncbi.nlm.nih.gov/pubmed/35854294 http://dx.doi.org/10.1186/s12935-022-02649-0 |
Ejemplares similares
-
TMED3/RPS15A Axis promotes the development and progression of osteosarcoma
por: Xu, Wei, et al.
Publicado: (2021) -
TMED3 promotes cell proliferation and motility in breast cancer and is negatively modulated by miR-188-3p
por: Pei, Jing, et al.
Publicado: (2019) -
TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR
por: Xie, An, et al.
Publicado: (2021) -
The circular RNA CDR1as regulate cell proliferation via TMED2 and TMED10
por: Yang, Xue, et al.
Publicado: (2020) -
Integrated analysis of immune-related genes in endometrial carcinoma
por: Wang, Yiru, et al.
Publicado: (2020)